VCs are starting to buy stakes in accounting firms with the intent of turbocharging them with AI. And they are sizing up ...

NerdWallet, Inc. does not offer advisory or brokerage services, nor does it recommend or advise investors to buy or sell particular stocks, securities or other investments. Buying stocks may seem ...

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...

A week into 2025, it’s clear that last year’s artificial intelligence (AI) startup boom isn’t slowing down. OpenAI CEO Sam ...

While the year 2024 was a double edged sword for the Indian fintech ecosystem, industry stakeholders predict a more positive ...

Healthcare experts should be on the lookout for trends related to digital health, prescription drug costs and healthcare ...

Check the time stamp on this data. Updated AI-Generated Signals for Visteon Corporation (VC) available here: VC. Type a few ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

VC deals in 2024 wrapped up with a total of $9.33B, a small increase from the previous year. Several large-scale deals ...

Visteon Co. (NASDAQ:VC – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen analysts that are currently covering the firm, MarketBeat.com reports. Five research analysts ...

In 2025, the healthtech sector will see a wave of exits, with mature, profitable companies leading IPOs as the market ...

Growing enthusiasm for AI, lower interest rates, and a boost from government at the state and federal levels should help.